GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04652076 |
Recruitment Status :
Recruiting
First Posted : December 3, 2020
Last Update Posted : April 12, 2024
|
Sponsor:
NETRIS Pharma
Collaborators:
Merck Sharp & Dohme LLC
Centre Leon Berard
Information provided by (Responsible Party):
NETRIS Pharma
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | October 30, 2025 |
Estimated Study Completion Date : | July 30, 2026 |